Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05384834
Other study ID # STUDY00001418
Secondary ID 1R03HL155253-01
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2022
Est. completion date April 3, 2023

Study information

Verified date October 2023
Source Emory University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the web tool #HerHeart's usability and feasibility in adolescent and young adult women (AYA) and the opinion of their healthcare providers (HCP).


Description:

The objective of the proposed research is to increase young women's perceived susceptibility to CVD and provide a cue to action to adopt heart-healthy behaviors. The aim of the proposed study is to evaluate the usability and initial feasibility of #HerHeart. The investigators will recruit 30 AYA participants and will ask 10 HCPs to evaluate the usability and feasibility of the web tool. The study population will include female patients ages 13-21 years from the CHOA Adolescent Medicine Practice and Grady Teen Health Program. Part of our study population will be considered vulnerable (children under the age of 18 years). Subjects will be recruited via phone in advance of a clinical visit, from the waiting rooms of each clinic at the time of their appointment (in-person) or via Zoom at a time scheduled after their telehealth appointment (virtual). Written informed consent will be obtained for subjects 18 years and older. For subjects younger than 18 years, written parental permission (unless doing so would violate the adolescents' right to privacy, in which the Waiver of Parental Permission will be invoked) and written informed assent will be obtained. All consent procedures will take place in a private research room of each clinic (for in-person visits) or via Zoom videoconferencing (for virtual visits). Participants who agree to participate will attend a study visit at the Emory Children's Center Research Unit. Data for this study will be collected from participants via surveys/questionnaires, and semi-structured interviews that will be audio-recorded. Data collected will include demographic information, cardiovascular disease risk information, health metrics (BMI, blood pressure), cognitive data (perceived stress, quality of life), and participant feedback on a mobile app intervention. All subjects will receive a study identification number. Only the PI will have the codes linking the study identification numbers to subjects and these codes will be stored in a locked cabinet. All data will be collected in a private research room in the clinics (in-person visits) or in a password-protected Zoom videoconference (virtual). All study staff will complete biomedical or socio-behavioral training through the Collaborative IRB Training Initiative Program (CITI). Data will be stored on the Emory servers in password-protected files.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date April 3, 2023
Est. primary completion date April 3, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 13 Years and older
Eligibility Inclusion Criteria (AYAs): - Patient at CHOA Hughes Spalding Adolescent Medicine Practice or the Grady Health System Teen Program - Age 13-21 years - Self-identifying as non-Hispanic Black or White race (inclusive of Hispanic ethnicity) - Self-identifying as female - Visit type is annual wellness/health check, behavioral/mental health, or reproductive/gynecological health - Consistent access to a mobile device with internet capability Exclusion Criteria (AYAs): - Cognitive impairment limiting ability to complete study procedure - Spoken and written language other than English - Diagnosis of hypertension, diabetes, or hyperlipidemia requiring medications, or atherosclerotic cardiovascular disease - Past or current diagnosis of a DSM-V eating disorder - Diagnosis of schizophrenia, bipolar disorder, or psychiatric hospitalization in the past 12 months - Pregnant at the time of the study. Inclusion Criteria (HCPs) to complete feasibility surveys: - Clinical team member (physician or nurse practitioner, nurse, social worker, psychologist, health educator, medical assistant, dietitian) at the CHOA Hughes Spalding Adolescent Medicine Practice or the Grady Health System Teen Program - Practicing at one of the study sites at least twice per month on average over the past year Exclusion Criteria (HCPs) - Member of the research study team

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
#HerHeart tool
An integrated application consisting of a lifestyle-based CVD risk assessment and companion behavioral intervention. It will be administered at baseline and 3 months follow-up.

Locations

Country Name City State
United States Children's Healthcare of Atlanta - Hughes Spalding Research Room Atlanta Georgia
United States Grady Health System Atlanta Georgia

Sponsors (2)

Lead Sponsor Collaborator
Emory University National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary #HerHEART Risk Score in AYA From Baseline Risk is assessed based on answers surrounding the most critical diet and lifestyle factors that can influence a person's CVD risk. The factors include exercise, intake of fruits, vegetables, grains, nuts, sugary beverages and red/processed meats, and exercise. The Healthy Heart Score algorithm will be used to calculate the relative percent risk score of participants. Participants with a higher percent risk score have a higher risk for CVD based on their current reported habits. Those at low risk will have a risk score <10%, moderate risk a risk score between 10 and 15%, and high risk a score above 15%. Baseline, 3 months post-enrollment
Primary Overall Composite of Diet Score Diet score = (0.03626 × grams/d of cereal fiber + 0.18283 [if fruits + vegetables =3 servings/d] + 0.14522 [if nuts 0.1-1 servings/d + 0.2444 [if nuts >1 servings/d]- 0.14631 × servings/d of sugar-sweetened beverages - 0.15624 × servings/d of red and processed meats)*10 A higher score implies better diet quality. An increase in diet score correlates with a better outcome. Baseline, 3 months months post-enrollment
Primary Fruit and Vegetable Intake Intake will be measured with number of servings per day. Increase in servings/day correlates with a better outcome. Baseline, 3 months post- post-enrollment
Primary Red and Processed Meats Intake Intake will be measured with number of servings per day. A decrease in consumption is associated with a better outcome. Baseline, 3 months post-enrollment
Primary Sugar and Sweetened Beverages Intake will be measured with number of servings per week. A decrease in consumption is associated with a better outcome. Baseline, 3 months post-enrollment
Primary Nut Consumption Intake will be measured with number of servings per week. An increase in intake is associated with a better outcome. Baseline, 3 months post-intervention
Primary Alcohol Consumption Number of participants who consume alcohol will be collected. No alcohol consumption is associated with a better outcome. Baseline, 3 months post-enrollment
Primary Nicotine Use Self-reported smoker status will be obtained and classified as: Never smoke, used to smoke, current smoker. Investigators will look at changes in smoking status where a decrease in use is associated with a better outcome. Baseline, 3 months post-enrollment
Primary Cereal Fiber Consumption of cereal will be measured in g/day. An increase in cereal fiber is associated with a better outcome. Baseline, 3 months post-enrollment
Primary Physical Activity Physical activity will be measured in number of hours per week. Increase in physical activity associated with a better outcome. Baseline, 3 months post-enrollment
Secondary BMI From Baseline AYA participant's BMI will be measured during the clinic appointment when participant is recruited. AYA participants will then be asked to return for a study visit 3 months post intervention where their BMI will be measured again. Change in BMI will be measured with a decrease in BMI being associated with a positive outcome and an increase in BMI being associated with a negative outcome. Baseline, 3 month post-enrollment
Secondary Systolic Blood Pressure (BP) From Baseline AYA participants' systolic BP (SBP) will be measured during the clinic appointment when the participant is recruited. AYA participants will then be asked to return for a study visit 3 months post-intervention where their BP will be measured again. Change in SBP will be measured with a decrease in SBP being associated with a positive outcome and an increase in SBP being associated with a negative outcome. Baseline, 3 month post-enrollment
Secondary Diastolic Blood Pressure (BP) From Baseline AYA participants' diastolic BP (DBP) will be measured during the clinic appointment when the participant is recruited. AYA participants will then be asked to return for a study visit 3 months post-intervention where their BP will be measured again. Change in DBP will be measured with a decrease in diastolic BP being associated with a positive outcome and an increase in BP being associated with a negative outcome. Baseline, 3 month post-enrollment
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)